NCT04651153已完成1 期
A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 2
- 主要终点
- Incidence of Treatment-emergent Adverse Events (TEAEs) in healthy male participants
研究概览
简要总结
The primary purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB7853 in healthy male study participants and to evaluate the safety and tolerability of multiple ascending doses of UCB7853 administered in study participants with Parkinson's Disease (PD)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Part 1 (healthy participants):
- •Participant must be male and 18 to 55 years of age inclusive
- •Body weight within 50 kg to 110 kg and body mass index (BMI) within the range 18.0 to 30.0 kg/m^2 (inclusive)
- •Participant must be healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
- •Participant has clinical laboratory test results within the reference ranges of the laboratory
- •Part 2 (participants with Parkinson's Disease):
- •Participant must be 40 to 80 years of age, inclusive, at the time of signing the informed consent form (ICF)
- •Participant may be male or female
- •Participant must have body weight of between 50 and 110 kg and a body mass index within the range of 18 to 32 kg/m^2 (inclusive)
- •Participant must have a clinical diagnosis of Parkinson's disease (PD) according to the Movement Disorders Society criteria. The following diagnostic criteria must be met: Bradykinesia AND at least ONE of the following: muscular rigidity or resting tremor
- •Participant must have a Hoehn and Yahr Stage of ≤3
- •Participant must be either untreated, or treated with a stable regimen (at least 4 weeks prior to Baseline Visit) of antiparkinsonian drugs and is expected to remain on this regimen for the duration of the study
- •Participant must be in good physical and mental health, in particular not affected by any neurological disorder other than Parkinson's disease (PD), in the opinion of the Investigator, determined on the basis of medical history and a general clinical examination at Screening
- •Participant has clinical laboratory test results within the reference ranges of the laboratory
排除标准
- •Part 1 (healthy participants):
- •Participant has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, pancreatic, musculoskeletal, genitourinary, immunological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
- •Participant has a known hypersensitivity to any components of the study medication or comparative drugs
- •Participant has any clinically relevant abnormal findings in physical examination, laboratory tests, or vital signs, which, in the opinion of the Investigator, may place the participant at risk because of participation in the study
- •Participant has any clinically relevant brain magnetic resonance imaging (MRI) abnormality at Screening
- •Part 2 (participants with Parkinson's Disease):
- •Participant has a diagnosis of a significant Central nervous system (CNS) disease other than PD or history of epilepsy or seizure disorder other than febrile seizures as a child
- •Study participant has a history of levodopa-induced motor fluctuations or dyskinesia expected to interfere with his/her ability to participate in the study
- •Participant has a known hypersensitivity to any components of the study medication or comparative drugs
- •Study participant has had prior surgical treatment for PD involving intracranial surgery or implantation of a device (including deep brain stimulation) or duodopa
- •Participant has any clinically relevant abnormal findings in physical examination (other than symptoms of PD), laboratory tests, or vital signs, which, in the opinion of the Investigator, may place the participant at risk because of participation in the study
- •Participant has any clinically relevant brain MRI abnormality at Screening
研究组 & 干预措施
UCB7853
Experimental
Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
干预措施: UCB7853 (Drug)
Placebo
Placebo Comparator
Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
干预措施: Placebo (Other)
结局指标
主要结局
Incidence of Treatment-emergent Adverse Events (TEAEs) in healthy male participants
时间窗: From Day 1 to the End of Study Visit (Day 141), Part 1)
A treatment-emergent Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
Incidence of Treatment-emergent Adverse Events (TEAEs) in participants with Parkinson's Disease
时间窗: From Day 1 to the End of Study Visit (Day 197), Part 2
A treatment-emergent Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
次要结局
- Cmax of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
- Cmax of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from Day 57 to the End of Study Visit (Day 197), Part 2)
- AUC of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
- AUC(0-t) of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
- AUC(0-t) of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from Day 57 to Day 85, Part 2)
- tmax of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
- tmax of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from from Day 57 to the End of Study Visit (Day 197), Part 2)
- t1/2 of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
- CL of UCB7853 after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from from Day 1 to the End of Study Visit (Day 141), Part 1)
- CSF/serum UCB7853 concentration ratio on Day 63 (Part 2)(Day 63 (Part 2))
- CL of UCB7853 after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from from Day 57 to Day 85, Part 2)
- Vz of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from from Day 1 to the End of Study Visit (Day 141), Part 1)
- CSF/serum UCB7853 concentration ratio on Day 7 (Part 1)(Day 7 (Part 1))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477Healthy VolunteersNCT02870400Regeneron Pharmaceuticals41
进行中（未招募）
1 期
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy ParticipantsHealthyNCT05501717Alexion Pharmaceuticals, Inc.48
Unknown
1 期
A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese SubjectsSchizophreniaNCT04839926Jiangsu Nhwa Pharmaceutical Co., Ltd.60
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT03945279Biogen49
已完成
1 期
Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)Immune Thrombocytopenia PurpuraNCT01963260Merck Sharp & Dohme LLC50